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Introduction {#sec1}
============

Tumors are avid glutamine consumers, and the versatile functions of glutamine within the cell make it a central nutrient for many cancers. After import, glutamine can donate its carbons for synthesis of amino acids and fatty acids and its nitrogen to synthesis of nucleotides, thereby directly supporting the accumulation of cellular building blocks ([@bib3], [@bib14], [@bib21]). Glutamine also supports the generation of cellular energy, as it can be metabolized via glutamate to α-ketoglutarate, providing substrates for the citric acid cycle and ATP formation ([@bib3], [@bib14]). Furthermore, glutamine regulates cell signaling, as it can be rapidly exported out of the cell in exchange for essential amino acids that directly activate mTOR, thereby inducing protein translation and cell growth ([@bib3], [@bib14], [@bib21]).

The pleiotropic role of glutamine in cancer cells has made glutamine uptake and metabolism attractive therapeutic targets, and several pharmacological approaches to limiting glutamine uptake and metabolism in tumor cells have been undertaken. Inhibition of the glutamine transporters SLC1A5 ([@bib12], [@bib42]) and SLC7A5 ([@bib25]) and various steps in glutaminolysis (glutaminase ([@bib19]), aminotransferases ([@bib28]) as well as glutamate dehydrogenase ([@bib26])) have all displayed anti-tumor activity in preclinical models. These approaches share a tumor-centric methodology, interfering at the level of the tumor cell.

Glutamine is the most abundant amino acid in the circulation, constituting around 20% of the free amino acid pool ([@bib3]). More than 70% of the circulating glutamine derives from skeletal muscle ([@bib34]) where it is either released from proteins by proteolysis or through de novo synthesis by glutamine synthetase (GS) ([@bib16], [@bib18], [@bib29], [@bib41]). Other tissues such as lung ([@bib38]), liver ([@bib43]), and adipose tissue ([@bib36]) also have the capacity for glutamine release, yet their contributions to the plasma glutamine pool are under normal conditions modest. The majority of glutamine consumed in the diet is retained by cells in the intestinal mucosa and does not reach the circulation ([@bib7], [@bib44]). Thus, release from skeletal muscle is the primary source of glutamine in serum.

Exercise has the potential to regulate serum glutamine levels, yet the effect depends on the intensity and duration of the exercise intervention. Acute exercise and mild/moderate exercise interventions have yielded varying results, whereas substantial documentation exists for reduced serum glutamine levels after prolonged or strenuous exercise ([@bib2], [@bib10], [@bib20], [@bib27]). The mechanism behind this observation is not completely understood but could be explained by reduced glutamine synthesis in the muscle, reduced glutamine release from muscle, or by increased glutamine uptake by other tissues ([@bib40]).

During the 90s, it was hypothesized that exercise-induced lowering of plasma-glutamine could explain post-exercise immune changes ([@bib33]). Glutamine intervention studies did, however, not restore exercise-induced immune perturbations ([@bib22]). Here, we suggest that glutamine may represent a possible link between exercise and cancer. By lowering serum glutamine, exercise might represent a non-pharmacological approach to limiting the access of tumor cells to an important nutrient.

In this study, we hypothesized that lowering serum glutamine levels by exercise might starve tumors of glutamine, thereby contributing to the inhibitory effect of exercise on tumor growth.

Results {#sec2}
=======

Systemic Glutamine Availability Controls Tumor Growth {#sec2.1}
-----------------------------------------------------

To investigate the importance of circulating glutamine levels for tumor growth, we limited the access of tumors to glutamine by treating tumor-bearing mice with methionine sulfoximine (MSO), a pharmacological inhibitor of glutamine synthetase (GS). We used two different syngeneic murine cancer models, Lewis lung carcinoma (LLC) and triple-negative breast cancer (E0771), which both harbor mutations in Kras ([@bib1], [@bib45]) known to be associated with glutamine dependence ([@bib17]), and which both showed markedly reduced cell proliferation when cultured in medium lacking glutamine ([Figures 1](#fig1){ref-type="fig"}A and 1F). In the tumor-bearing mice, MSO administration significantly lowered serum glutamine levels in mice with both tumor types (LLC: −57%, p \< 0.001, [Figure 1](#fig1){ref-type="fig"}B; and E0771: −48%, p \< 0.001, [Figure 1](#fig1){ref-type="fig"}G) and inhibited tumor growth as quantified by both tumor weight (LLC:−58%, p \< 0.01, [Figure 1](#fig1){ref-type="fig"}C; and E0771:−34%, p = 0.11, [Figure 1](#fig1){ref-type="fig"}H) and tumor volume (LLC:−62%, p \< 0.01, [Figure 1](#fig1){ref-type="fig"}D; and E0771:−44%, p = 0.056, [Figure 1](#fig1){ref-type="fig"}I). For both tumor types, serum glutamine concentration significantly correlated with tumor weight ([Figures 1](#fig1){ref-type="fig"}E and 1J).Figure 1Reduced Access to Glutamine Inhibits Cancer Growth In Vitro and In VivoCell proliferation of murine lung cancer (Lewis Lung carcinoma \[LLC\]) (A) and breast cancer (E0771) (F) cells in growth medium with and without glutamine. Data represent absorbance at 490 nm after an MTS assay. Serum glutamine levels in mice with LLC tumors with and without MSO treatment (B) (CON = 14, MSO = 14, unpaired Student\'s t-test). Size at takedown (tumor growth for 16 days) of LLC tumors from mice with and without MSO treatment quantified by weight (C) and volume (D) (CON = 14, MSO = 14, unpaired Student\'s t-tests). Pearson correlation (E) of LLC tumor weight and serum glutamine levels. Serum glutamine levels in mice with breast cancer (E0771) tumors with and without MSO treatment (G) (CON = 12, MSO = 12, unpaired Student\'s t-test). Size at takedown (tumor growth for 16 days) of E0771 tumors from mice with and without MSO treatment quantified by weight (H) and volume (I) (CON = 12, MSO = 12, unpaired Student\'s t-tests). Pearson correlation (J) of breast cancer (E0771) tumor weight and serum glutamine levels. Data are depicted as means +/− SD. ∗p \< 0.05, ∗∗p \< 0.01, ∗∗∗p \< 0.001.

MSO Treatment Regulates Glutamine Metabolism and Atrophic Signaling {#sec2.2}
-------------------------------------------------------------------

LLC-tumor-bearing mice treated with MSO exhibited a significant intratumoral upregulation of the expression of glutamine transporters SLC1A5 (+83%, p \< 0.001) and SLC7A5 (3-fold, p \< 0.001) ([Figure 2](#fig2){ref-type="fig"}A), suggesting that these tumors attempt to maintain sufficient glutamine supply by increasing the number of transporters once serum glutamine levels become scarce. Of note, GS expression was not induced by MSO, suggesting that these tumors rely heavily on external glutamine supply. In tibialis anterior muscle of the same mice, MSO treatment strongly upregulated GS (+82%, p \< 0.01) and the glutamine transporters SLC1A5 (+56%, p \< 0.01) and SLC38A3 (+53%, p \< 0.001) ([Figure 2](#fig2){ref-type="fig"}B), reflecting a compensation for the inhibition of GS activity. Interestingly, blocking glutamine synthesis also resulted in reduced intramuscular expression of the atrophy marker atrogin-1 (−44%, p \< 0.001) ([Figure 2](#fig2){ref-type="fig"}C) and activin signaling, i.e. activin receptor 2A (AR2A) (−12%, p \< 0.001) and activin receptor 2B (AR2B) (−39%, p \< 0.001) ([Figure 2](#fig2){ref-type="fig"}D), suggesting a link between glutamine metabolism and muscle wasting/maintenance. However, we did not detect any tumor-induced weight loss in this experiment ([Figure 2](#fig2){ref-type="fig"}E).Figure 2Blocking GS Activity Affects Glutamine Metabolism and Transport and Atrophic Signaling in Tumors and MuscleExpression of genes involved in glutamine transport and metabolism in LLC tumors from mice with and without MSO treatment (A) (CON = 13, MSO = 13, unpaired Student\'s t-tests). Gene expression of glutamine synthetase (GS) and glutamine transporters (B), atrophy markers (C), and myostatin signaling cascade (D) in tibialis anterior muscle from mice with LLC tumors with and without MSO treatment (CON = 13, MSO = 13, unpaired Student\'s t-tests). Change in body weight (excluding tumor weight) in the period of tumor challenge (tumor growth for 16 days) in mice with LLC tumors with and without MSO treatment (E) (CON = 14, MSO = 14, paired Student\'s t-tests of weight at tumor induction and takedown). Data are depicted as means +SD. ∗p \< 0.05, ∗∗p \< 0.01, ∗∗∗p \< 0.001.

Acute and Long-Term Exercise Training Regulates Glutamine Availability and Metabolism {#sec2.3}
-------------------------------------------------------------------------------------

A physiological way to reduce circulating glutamine levels is through exercise. In accordance, we found that 45 min of swimming in untrained and exercise-trained (access to running wheels for four weeks) tumor-free C57BL/6 mice induced an acute drop (−27% for untrained mice, p \< 0.01, and −39% for trained mice, p \< 0.001) in serum glutamine concentration, which persisted at least 2 h after the intervention ([Figure 3](#fig3){ref-type="fig"}A). Similarly, mice with E0771 tumors exhibited reduced serum glutamine concentration (−27%, p \< 0.001) 2 h after a 45 min swimming intervention compared with a group of tumor-bearing control mice that did not swim ([Figure 3](#fig3){ref-type="fig"}B). Serum glutamine levels in mice sampled 24 and 48 h after swimming did not differ from the control group.Figure 3Acute Swimming Reduces Serum Glutamine and Voluntary Wheel Running Reduces Tumor Growth and Affects Glutamine Synthesis and Transport in Muscle and TumorSerum glutamine levels (A) from trained and untrained mice (+/− 4 weeks of voluntary wheel running) sampled before (CON), immediately after (0), and 2 h into the recovery (2) of a 45-min swimming intervention (untrained = 9, trained = 7, two-way ANOVA with repeated measures, Bonferroni correction). Serum glutamine levels (B) from four groups of mice with E0771 tumors, taken down at the indicated time points after a 45-min swimming intervention (CON = 9, 2 h = 10, 24 h = 10, 48 h = 9, one-way ANOVA with Bonferroni correction). Gene expression of GS and glutamine transporters (C) in tibialis anterior muscle from mice in (B) (one-way ANOVA with Bonferroni correction). Gene expression of GS and glutamine transporters (D) in E0771 tumors from the same mice as in (B) (one-way ANOVA with Bonferroni correction). Size at takedown (tumor growth for 15 days) of E0771 tumors quantified by weight (E) and volume (F) from sedentary (CON) and wheel running (EX) C57BL/6 mice (CON = 18, EX = 18, unpaired Student\'s t-tests). Serum glutamine levels (G) in mice from E and F (CON = 18, EX = 18, unpaired Student\'s t-tests). Gene expression of GS and glutamine transporters (H) in tibialis anterior muscle from mice in E and F (CON = 16, EX = 14, unpaired Student\'s t-tests). Data are depicted as means +/− SD, ∗p \< 0.05, ∗∗p \< 0.01, ∗∗∗p \< 0.001.

Next, we evaluated how acute exercise could regulate intramuscular and intratumoral glutamine synthesis and transport. In mice with E0771 tumors, the reduction in serum glutamine 2 h after swimming coincided with increased intramuscular expression of GS (+45%, p \< 0.01), SLC7A5 (4-fold, p \< 0.001) and SLC38A3 (+21%, p \< 0.05) ([Figure 3](#fig3){ref-type="fig"}C). In mice sampled after 24 h, SLC38A3 expression was significantly reduced (−20%, p \< 0.05) compared with controls, whereas GS, SLC1A5, and SLC7A5 were not significantly altered ([Figure 3](#fig3){ref-type="fig"}C). In tumors from these mice, we observed modest regulation of the expression of GS (+17%, p \< 0.05) and SLC7A5 (+17%, p \< 0.05) 2 h after the swimming intervention, whereas SLC1A5 and SLC38A3 did not differ from control levels ([Figure 3](#fig3){ref-type="fig"}D). After 24 and 48 h no differences were detected ([Figure 3](#fig3){ref-type="fig"}D). This suggests that acute exercise directly impacts glutamine synthesis and transport in tumor and muscle tissue with roughly the same pattern but to a larger extent in the muscles.

We went on to investigate the effect of long-term training. C57BL/6 mice were randomized to cages with and without running wheels for four weeks and subsequently inoculated with E0771 tumors. Voluntary wheel running significantly reduced tumor growth compared with control mice as quantified by tumor weight (−43%, p \< 0.01, [Figure 3](#fig3){ref-type="fig"}E) and tumor volume (−42%, p \< 0.01, [Figure 3](#fig3){ref-type="fig"}F). Serum glutamine levels obtained at termination of the experiment did not differ between control and wheel running mice ([Figure 3](#fig3){ref-type="fig"}G). Muscles from wheel-running mice had significantly reduced expression of GS (−46%, p \< 0.001) and the glutamine transporters SLC1A5 (−29%, p \< 0.001) and SLC38A3 (−41%, p \< 0.001) ([Figure 3](#fig3){ref-type="fig"}H) compared with controls, suggesting that exercise resulted in a long-term adaptive suppression of the expression of GS and glutamine transporters in muscles.

Voluntary Wheel Running Prevents Tumor-Induced Weight Loss {#sec2.4}
----------------------------------------------------------

Next, we set out to investigate muscle maintenance in a cachexia-inducing tumor type. C57BL/6 mice were randomized to cages with and without running wheels, and after four weeks inoculated with LLC cells. Wheel running significantly reduced tumor growth in this tumor model as quantified by both tumor weight (−90%, p \< 0.01, [Figure 4](#fig4){ref-type="fig"}A) and tumor volume (−91%, p \< 0.01, [Figure 4](#fig4){ref-type="fig"}B). In order to shed light on the pronounced tumor growth suppression in this mouse model, we opted to perform RNA sequencing to elucidate genome-wide regulation in the tumors. RNA sequencing of LLC tumor tissue revealed virtually no differential regulation of intratumoral gene expression between tumors from the control and exercise groups as evidenced by principal component analyses ([Figures 4](#fig4){ref-type="fig"}C and [S1](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc2){ref-type="supplementary-material"}). Accordingly, targeted PCR against glutamine transporters found no significant differences in the expression patterns in LLC tumors in response to voluntary wheel running ([Figure 4](#fig4){ref-type="fig"}D).Figure 4Voluntary Wheel Running Reduces Tumor Growth and Prevents Tumor-Induced Weight Loss and Intramuscular Changes in Glutamine Transport and Catabolic SignalingSize at takedown (tumor growth for 23 days) of LLC tumors quantified by weight (A) and volume (B) from sedentary and wheel running C57BL/6 mice (CON = 8, EX = 13, unpaired Student\'s t-tests). Principal Component Analysis of intratumoral gene expression profiles (C) obtained by RNA-sequencing of tumors in (A and B) (see also [Figure S1](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc2){ref-type="supplementary-material"}). Gene expression of GS and glutamine transporters (D) in tumors in (A and B). Change in body weight in the period of tumor challenge (tumor growth for 23 days) (E) in sedentary and wheel-running C57BL/6 mice with and without LLC tumors (no tumor = 12, CON = 8, no tumor + EX = 10, EX = 13, two-way ANOVA with Bonferroni correction, p = 0.003 for interaction. \$ indicates a statistically significant weight change in a paired Student\'s t-test of weight at tumor induction and takedown). Percentage change in lean body mass (F) and fat mass (G) during tumor challenge obtained by DXA scanning of mice from Figure E prior to tumor induction and at takedown (tumor growth for 23 days) (two-way ANOVA with Bonferroni correction. \$ indicates a statistically significant change in lean body mass and fat mass in a paired Student\'s t-test of lean and fat mass at tumor induction and takedown). Gene expression of myostatin signaling cascade (H), GS, and glutamine transporters (I) and atrophy markers (J) in tibialis anterior muscle of mice from (E) (two-way ANOVA with Bonferroni correction, p-values for interaction: myostatin = 0.0096, SMAD3 = 0.092, SMAD7 = 0.019, SLC1A5 = 0.017, atrogin-1 = 0.058, MuRF1 = 0.042). Protein expression of GS, glutamine transporters, and atrophy markers (K) in gastrocnemius muscle of mice from (E). Data represent fold changes in Western blot band intensity. The signal for the protein of interest in each lane was normalized to the total protein amount in the same lane. Data represent the mean of two independent experiments (two-way ANOVA with Bonferroni correction). Representative Western blot images (L) of GS, glutamine transporters, and atrophy markers quantified in (K). Data are depicted as mean ± SD. ∗p \< 0.05, ∗∗p \< 0.01, ∗∗∗p \< 0.001, \$ p \< 0.05, \$\$ p \< 0.01.

The LLC-tumor-bearing mice exhibited a significant weight loss in the period of tumor burden (−1.14 g, p \< 0.01), which was completely prevented by wheel running (p \< 0.01 for interaction in a two-way ANOVA) ([Figure 4](#fig4){ref-type="fig"}E). The increase in lean body mass in the period of tumor burden observed across the study in control mice tended to be attenuated in LLC-tumor-bearing mice (p = 0.087), whereas it was normalized by wheel running ([Figure 4](#fig4){ref-type="fig"}F). Tumor-free mice exhibited reductions in fat mass but in the same period an increase in lean body mass ([Figure 4](#fig4){ref-type="fig"}G).

When exploring the muscular signaling in these mice, we found that LLC tumors induced the mRNA expression of SLC7A5 (+57%, p \< 0.01) and tended to induce the expression of SLC1A5 (+16%, p = 0.093) ([Figure 4](#fig4){ref-type="fig"}I). This induction of glutamine transporters by LLC tumors was abolished by wheel running ([Figure 4](#fig4){ref-type="fig"}I). In continuation, the presence of LLC tumors induced the expression of the atrophy markers atrogin-1 (+50%, p \< 0.05) and MuRF1 (+63%, p \< 0.05) ([Figure 4](#fig4){ref-type="fig"}J) and myostatin signaling (myostatin: +57%, p \< 0.001, activin receptor 2A: +26%, p \< 0.001, and SMAD3: +73%, p \< 0.001) ([Figure 4](#fig4){ref-type="fig"}H). These inductions were completely abolished with wheel running ([Figures 4](#fig4){ref-type="fig"}H and 4J), consistent with the observed weight loss and impaired gain of lean mass. No statistically significant differences were observed in the muscular protein expression of GS, the glutamine transporter SLC38A3, or the atrophy markers atrogin-1 and Murf1 ([Figure 4](#fig4){ref-type="fig"}K).

Wheel Running Prevents Tumor-Induced Weight Loss Independently of Tumor Size {#sec2.5}
----------------------------------------------------------------------------

Because wheel running had a marked effect on tumor growth, we confirmed the effect of voluntary wheel running on tumor-induced weight loss and intramuscular signaling in a separate experiment where the mice were euthanized when tumor volume was estimated to 1 cm^3^ by external calipers, yielding two groups of mice with the same average tumor size ([Figures 5](#fig5){ref-type="fig"}A and 5B). In line with the previous experiment, LLC tumors induced a significant weight loss of −1.13 g (p \< 0.01), which was completely abolished by voluntary wheel running ([Figure 5](#fig5){ref-type="fig"}C), despite similar tumor burden in the control and exercise groups. In the control group, tumor size correlated with the observed weight loss (p \< 0.05) ([Figure 5](#fig5){ref-type="fig"}D), whereas this correlation was abolished in the wheel running group. As before, the intramuscular expression levels of glutamine transporters SLC1A5 (−15%, p = 0.053) and SLC7A5 (−32%, p \< 0.05) ([Figure 5](#fig5){ref-type="fig"}E), as well as the atrophy marker MuRF1 (−52%, p \< 0.05) ([Figure 5](#fig5){ref-type="fig"}F) and myostatin signaling (myostatin: −31%, p \< 0.01, and SMAD3:−20%, p \< 0.01) ([Figure 5](#fig5){ref-type="fig"}G) were reduced by wheel running, suggesting that the regulation by wheel running can overcome the tumor-induced changes independently of tumor size.Figure 5Voluntary Wheel Running Prevents Tumor-Induced Weight Loss and Regulates Intramuscular Signaling Independently of Tumor SizeSize at takedown of LLC tumors quantified by weight (A) and volume (B) from sedentary and wheel running C57BL/6 mice (CON = 10, EX = 23, unpaired Student\'s t-tests) (mean period of tumor growth: CON = 23.3 days +/− 4.09, EX = 23.5 days +/−4.9). Change in body weight in the period of tumor challenge (excluding tumor weight) (C) in mice from (A and B) (CON = 10, EX = 23, unpaired Student\'s t-test. \$ indicates a statistically significant weight change in a paired Student\'s t-test of weight at tumor induction and takedown). Linear regression (D) of tumor weight versus change in body weight in mice from (A and B). Gene expression of GS and glutamine transporters (E), atrophy markers (F), and myostatin signaling cascade (G) in tibialis anterior muscle from mice in (A and B) (CON = 10, EX = 21, unpaired student\'s t test). Data are depicted as mean ± SD. ∗p \< 0.05, ∗∗p \< 0.01, ∗∗∗p \< 0.001, \$ p \< 0.05, \$\$ p \< 0.01.

Global Gene Expression in Muscles {#sec2.6}
---------------------------------

Given the protection against tumor-induced weight loss by wheel running, we explored intramuscular exercise adaptations in response to voluntary wheel running. RNA sequencing of muscle tissue from the mice with similarly sized LLC tumors showed significant changes in the muscular transcription of 265 genes and a clear separation between the control and exercise groups by principal component analysis ([Figures 6](#fig6){ref-type="fig"}A and [S2](#mmc1){ref-type="supplementary-material"} and [Table S2](#mmc3){ref-type="supplementary-material"}). Subsequent pathway analysis revealed that the upregulated genes were mostly associated to myogenesis and oxidative phosphorylation ([Figure 6](#fig6){ref-type="fig"}B), demonstrating that mice with access to running wheels exhibited classical intramuscular exercise adaptations despite LLC tumor burden. Interestingly, genes related to alternative splicing were also identified in the pathway analysis ([Figure 6](#fig6){ref-type="fig"}C). In support of these findings, we measured the splice variants of PGC-1α, which demonstrated differential expression with wheel running and tumor burden ([Figure 6](#fig6){ref-type="fig"}D).Figure 6Voluntary Wheel Running Induces Classical Intramuscular Exercise Adaptations in Tumor-Bearing MicePrincipal component analysis of intramuscular gene expression profiles (A) obtained by RNA-sequencing of tibialis anterior muscle from mice in [Figures 5](#fig5){ref-type="fig"}A and 5B (CON = 10, EX = 14 \[samples selected based on which mice ran the most\]) (see also [Figure S2](#mmc1){ref-type="supplementary-material"} and [Table S2](#mmc3){ref-type="supplementary-material"}). Heatmaps of ranks for hallmark (B) and Kyoto Encyclopedia of Genes and Genomes (KEGG) (C) gene-sets associated with genes significantly downregulated (left column), upregulated (right column), or regulated independently of direction (middle column) in muscle tissues from mice in [Figures 5](#fig5){ref-type="fig"}A and 5B. Only the 11 top ranked (most regulated) gene-sets are shown (out of 50 for hallmarks pathways, out of 186 for KEGG). The more red the color, the higher the rank. Gene expression of PGC-1α splice variants (D) in tibialis anterior muscle from mice in [Figure 5](#fig5){ref-type="fig"}E; n.d., not detectable. Data are depicted as mean +SD. ∗p \< 0.05, ∗∗p \< 0.01, ∗∗∗p \< 0.001.

Co-regulation of Glutamine and Myostatin in Muscle Cells {#sec2.7}
--------------------------------------------------------

Across the murine studies, we observed concurrent regulation of glutamine metabolism and myostatin/atrophy signaling. Thus, to explore any co-regulation we investigated the effect of myostatin stimulation and reduced glutamine availability on the expression of glutamine transporters in C2C12 myotubes. In accordance with others ([@bib46]) we found that differentiation of C2C12 myotubes in medium conditioned by cultured LLC cells yielded visibly thinner myotubes compared with C2C12 grown under control conditions ([Figure 7](#fig7){ref-type="fig"}A). To investigate if tumor-derived myostatin might be responsible for the tumor-induced expression of glutamine transporters in muscle observed in the murine studies, we stimulated fully differentiated C2C12 myotubes with recombinant myostatin (400 ng/mL) for 2.5 h. Myostatin reduced the expression of GS (−15%, p \< 0.001), SLC1A5 (−7%, p = 0.07), and SLC7A5 (−9%, p \< 0.01) ([Figure 7](#fig7){ref-type="fig"}B), suggesting that the tumor-induced upregulation of glutamine transporters in muscle is not driven by myostatin.Figure 7Co-regulation of Glutamine and MyostatinRepresentative pictures of C2C12 myotubes differentiated under control conditions or in 25% medium conditioned by LLC cells, stained for α-actinin (A). Gene expression of GS and glutamine transporters (B) in fully differentiated C2C12 myotubes after 2.5 h incubation with or without myostatin (400 ng/mL) (n = 8, unpaired Student\'s t-test). Gene expression of GS and glutamine transporters (C), atrophy markers (D), and myostatin signaling cascade (E) in fully differentiated C2C12 myotubes after 2.5 h incubation in medium containing the indicated concentrations of glutamine (n = 8, 1-Way ANOVA with Bonferroni correction). Data are depicted as mean +SD. ∗p \< 0.05, ∗∗p \< 0.01, ∗∗∗p \< 0.001.

Next, we exposed fully differentiated C2C12 myotubes to reduced glutamine availability in the cell medium. Compared with standard cell medium conditions (3.9 mM glutamine), 2.5 h of incubation in medium with 0.5 mM glutamine reduced the expression levels of GS (−9%, p \< 0.01), SLC1A5 (−17%, p \< 0.001), and SLC7A5 (−33%, p \< 0.001) ([Figure 7](#fig7){ref-type="fig"}C), whereas complete glutamine depletion for 2.5 h reduced the expression of GS (−10%) and induced the expression of SLC1A5 (+32%, p \< 0.001) and SLC7A5 (57%, p \< 0.001) ([Figure 7](#fig7){ref-type="fig"}C). This suggests that external glutamine availability regulates the expression of glutamine transporters in myotubes. Incubation of C2C12 cells in medium with 0.5 mM glutamine did not significantly affect the expression of atrophy markers ([Figure 7](#fig7){ref-type="fig"}D) or myostatin ([Figure 7](#fig7){ref-type="fig"}E) but reduced the expression of activin receptor 2A (−8%, p \< 0.05), activin receptor 2B (−12%, p \< 0.01), and SMAD3 (−13%, p \< 0.001) ([Figure 7](#fig7){ref-type="fig"}D). Complete glutamine depletion for 2.5 h induced the expression levels of atrogin-1 (+12%, p \< 0.05), tended to induce MuRF1 (+13%, p = 0.09) ([Figure 7](#fig7){ref-type="fig"}D), and induced activin receptor 2A (+8%, p \< 0.05), SMAD2 (+13%, p \< 0.05), and SMAD7 (+22%, p \< 0.01) ([Figure 7](#fig7){ref-type="fig"}E).

Discussion {#sec3}
==========

Here, we demonstrate that reducing glutamine availability, through either pharmacological treatment or voluntary wheel running, significantly attenuated the growth of two different syngeneic murine tumor models, respectively the triple-negative breast cancer model E0771 and the lung cancer model LLC. Both interventions decreased intramuscular mRNA expression of atrophy markers in tumor-bearing mice, resulting in a complete prevention of LLC tumor-induced weight loss with wheel running. Thus, our studies suggest that voluntary wheel running may preserve muscle mass in mice despite a large tumor burden by counteracting atrophic signaling and muscular glutamine release.

Regulation of tumor growth by limiting glutamine utilization has previously focused on drugs targeting intratumoral metabolism. Here, we aimed to regulate glutamine availability by addressing the systemic production. MSO treatment inhibits GS activity and in our study lowered glutamine levels in serum by approximately 50%. This markedly correlated with reduced growth of the two investigated tumor models, underscoring that tumor growth might be controlled by reducing glutamine availability. As a consequence, we observed that LLC tumors upregulated SLC1A5 and SLC7A5 expression. These two glutamine transporters are believed to be functionally coupled in tumors ensuring both glutamine import for intracellular glutaminolysis and export in exchange for essential amino acids and activation of cell growth via mTOR ([@bib6]). Upregulation of this transport system by MSO likely reflects a compensatory response by tumors to the reduced glutamine availability. In muscle tissue from LLC-tumor-bearing mice, we observed a significant reduced expression of the atrophy marker atrogin-1 and activin receptor 2A and 2B after MSO treatment, suggesting a link between glutamine metabolism and muscle wasting/maintenance.

Like MSO treatment, acute exercise, in the form of a 45-min swimming intervention, significantly reduced glutamine levels in serum in both tumor-free and E0771 tumor-bearing mice. The reduction in serum glutamine of about 30%--40% persisted at least 2 h into the recovery period and was restored to baseline levels after 24 h. Acute, transient changes in systemic factors, such as catecholamines and myokines, accompanying an acute exercise bout have previously been linked to the anti-cancer effect of exercise ([@bib15]). Our current paper suggests the addition of glutamine to the list of factors altered by acute exercise, which collectively contribute to an environment unfavorable to cancer growth and progression. In parallel, we found that swimming increased the expression of GS and glutamine transporters in muscle, whereas regulation in the tumor was less affected by exercise training. In continuation, we found that long-term training in the form of voluntary wheel running significantly reduced the growth of both LLC and E0771 tumors, and as after the acute swimming intervention, we hardly observed any differential gene expression in the tumors, wherease transcriptional adaptations did occur in muscle tissue.

Mice with E0771 tumors exhibited significantly reduced intramuscular expression of GS and glutamine transporters in response to voluntary wheel running, indicative of a long-term adaptive suppression of muscular expression of GS and glutamine transporters by exercise.

In muscle tissue, LLC tumors induced the mRNA expression of several components of the atrophic signaling cascade, as has been previously described ([@bib8]). Voluntary wheel running completely prevented this tumor-induced expression, in a pattern similar to the effect of MSO. Inhibition of myostatin signaling has in several mouse studies been shown to prevent tumor-induced cachexia and prolong survival ([@bib8], [@bib47]). Our findings are in full accordance with this and extend these previous findings by suggesting that the abolishment of tumor-induced mRNA expression of atrophy/myostatin in muscle tissue can be obtained by voluntary wheel running, resulting in prevention of tumor-induced weight loss. We did, however, not observe changes in the expression of atrophic markers on the protein level. In addition to the induced mRNA expression of atrophic markers, we observed an increased mRNA expression of the glutamine exporter SLC7A5 in the presence of LLC tumors ([@bib4], [@bib23]). Considering the dependence of LLC tumors on external glutamine supply, this might suggest that LLC tumors are able to directly influence glutamine export from skeletal muscle. It is generally accepted that cachexia-inducing tumors can reprogram the host metabolism in a manner that favors nutrient supply to the tumor at the expense of host tissue wasting ([@bib9], [@bib39]). Several tumor models have previously been documented to affect muscle glutamine synthesis and transport. In rats carrying methylcholanthrene-induced (MCA) fibrosarcoma, muscular GS activity and expression was increased, glutamine release from muscle increased, and intramuscular glutamine concentration was reduced ([@bib11]). Likewise, in rats carrying Walker 256 carcinosarcoma, skeletal muscle and plasma glutamine content decreased and release of glutamine from extensor digitorumlongus (EDL) muscle increased ([@bib35]). A recent tracer-experiment in mice revealed incorporation of muscle-derived glutamine into subcutaneous C26 tumors, possibly directly recruited by tumor-derived high-mobility group box 1 (HMGB1) protein release to the circulation ([@bib30]). Our experiments suggest that voluntary wheel running can counteract this tumor-induced regulation of glutamine export from skeletal muscle. Glutamine is the most abundant free amino acid in muscle tissue, estimated to make up more than 40% of the free intramuscular amino acid pool ([@bib5], [@bib31]). Additionally, it is incorporated into proteins, where it may account for between 4% and 14% of intact muscle protein depending on the mode of estimation ([@bib13], [@bib29]). Assuming that LLC tumors can increase glutamine release from skeletal muscle, usurping muscular glutamine could be one mechanism by which LLC tumors induce muscle wasting, simply by depleting the large intramuscular glutamine pool.

The proposition that an effect of exercise could be to starve tumors of a key factor for growth goes well with recent epidemiological data showing that exercise lowers the risk of cancer across histologies ([@bib32]). Also, in our study a prominent tumor inhibitory effect was found in two rather different tumor models, namely a lung cancer model and a triple-negative breast cancer model, in line with glutamine being important in tumor growth across histologies ([@bib12], [@bib19], [@bib25], [@bib42]). Recent evidence points to a number of effects of exercise that lead to tumor growth inhibition, as reviewed previously ([@bib24]), and the current paper adds to the list of factors that may explain the rather striking findings placing exercise as central in cancer prevention.

We have previously shown that voluntary wheel running can prevent tumor growth across a panel of murine tumors. In B16 malignant melanoma tumors, we identified a marked exercise-mediated upregulation of NK-cell infiltration into tumors as an underlying mechanism for exercise-mediated suppression of tumor growth ([@bib37]). In the present study, we did not find any exercise-induced expression of NK cell markers in LLC tumors (data not shown), underlying that exercise may influence tumor growth by different pathways dependent on tumor type.

In conclusion, we show that limiting glutamine availability, either pharmacologically or physiologically by wheel running, decreased tumor growth and reduced mRNA expression of atrophy markers in muscle from tumor-bearing mice. In continuation, we demonstrated a complete abolishment of LLC-tumor-induced weight loss by voluntary wheel running, independently of the effect of wheel running on tumor growth.

Limitations of the Study {#sec3.1}
------------------------

The LLC and E0771 tumor models applied in this project constitute transplantable syngeneic tumor models. A general limitation inherent to all transplantable tumor models is the bypassing of the initial steps in tumor development during which cells are transformed and starts neoplastic division. Accordingly, in the interventions with MSO and voluntary wheel running, potential effects on initial tumor development are not investigated with this approach. Thus, the present results exclusively represent effects on already transformed tumor cells, their establishment as solid tumors, and subsequent tumor growth.

Swimming and voluntary wheel running were applied as exercise interventions, thus representing both a forced and a voluntary type. Because the swimming intervention does represent forced exercise it is likely that a stress response was evoked in the mice during the 45 min of swimming. Thus, effects of the swimming intervention cannot necessarily be attributed solely to the exercise component of the intervention. To avoid subjecting the mice to the stress induced by single housing, mice were housed in pairs. Thus, for the voluntary wheel running intervention, the LCD Activity Wheel Counters only provide information about the daily distance covered per cage, whereas the distribution of this distance between two mice in a cage remains unknown. The average distances reported per mouse per day are thus approximations.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.

Data and Code Availability {#appsec3}
==========================

The accession number for the RNA-sequencing analysis of LLC tumor tissue reported in this paper is ArrayExpress: [E-MTAB-5311](array-express:E-MTAB-5311){#interref10}. The accession number for the RNA-sequencing analysis of murine muscle tissue reported in this paper is ArrayExpress: [E-MTAB-5974](array-express:E-MTAB-5974){#interref5}.

Supplemental Information {#appsec2}
========================

Document S1. Transparent Methods and Figures S1 and S2Table S1. Raw Data from RNA-Sequencing of LLC Tumor Tissue, Related to Figure 4List of genes from RNA-sequencing of LLC tumors from sedentary and wheel running C57BL/6 mice. The list includes gene identification, log fold change (logFC), average log-counts-per-million of each gene in the sample (AveExpr), p-values, and adjusted p-values.Table S2. Raw Data from RNA-Sequencing of Tibialis Anterior Muscle Tissue, Related to Figure 6List of genes from RNA-sequencing of tibialis anterior muscle from sedentary and wheel running C57BL/6 mice carrying LLC tumors grown to the same size. The list includes gene identification, log fold change (logFC), average log-counts-per-million of each gene in the sample (AveExpr), p-values, and adjusted p-values.
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